If you have been reading about BPC-157 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
=== Pharmacokinetics === Metabolism of ciprofol occurs primarily in the liver through oxidation, glucuronidation, and sulfation, resulting in the formation of the inactive metabolite M4-glucuronide, which is excreted renally. It is not necessary to adjust the dose in people with mild or moderate renal impairment, or in those with mild or moderate hepatic impairment. In elderly people, a slightly lower dose (0.3 mg/kg) appears to be similar in efficacy to the higher doses administered to younger people but is associated with fewer adverse effects. Ciprofol has a short elimination half-life, generally between 2 and 4 hours. Owing to its rapid metabolism and high clearance, the drug does not tend to accumulate in the body, even during prolonged infusions.
==== Skin and chronic wounds ==== Dermal regeneration involves the development of bioengineered skin substitutes and advanced wound dressings to treat deep third-degree burns, diabetic foot ulcers, and extensive chronic wounds. Unlike traditional occlusive dressings, regenerative skin scaffolds provide a temporary, porous extracellular matrix analog that coordinates cellular ingress, granulation tissue formation, and re-epithelialization. Commercially available matrices utilize decellularized human or bovine dermal matrices, synthetic biodegradable polymers (such as polycaprolactone), and naturally derived marine biomaterials, including acellular fish skin graphics rich in omega-3 fatty acids. These matrices are designed to modulate the localized inflammatory response, suppress bacterial colonization, and recruit host fibroblasts and keratinocytes to restore functional, vascularized skin tissue while minimizing scar formation.
On September 30, 2009, the NNSA announced that about two thirds of the special nuclear material (e.g., plutonium) at LLNL requiring the highest level of security protection had been removed from LLNL. The move was part of NNSA's efforts initiated in October 2006 to consolidate special nuclear material at five sites by 2012, with significantly reduced square footage at those sites by 2017. The federally mandated project intended to improve security and reduce security costs, as part of NNSA's overall effort to transform the Cold War era "nuclear weapons" enterprise into a 21st-century "nuclear security" enterprise. The original date to remove all high-security nuclear material from LLNL, based on equipment capability and capacity, was 2014. NNSA and LLNL then developed a timeline to remove this material earlier, and accelerated the completion date to 2012.
Sources: en.wikipedia.org
Interpretation for primary aldosterone deficiency The aldosterone response in the ACTH stimulation test is blunted or absent in patients with primary adrenal insufficiency including Addison's disease. The base value is usually in the mid-teens or less and rise to less than double the base value thus indicating primary hypoaldosteronism (sodium low, potassium and renin enzyme will be high) and is an indicator of primary adrenal insufficiency or Addison's disease.
The United States detonated an experimental device in the 1955 Operation Teapot "MET" test which used a plutonium/233U composite pit; its design was based on the plutonium/235U pit from the TX-7E, a prototype Mark 7 nuclear bomb design used in the 1951 Operation Buster-Jangle "Easy" test. Although not an outright fizzle, MET's actual yield of 22 kilotons was sufficiently below the predicted 33 kt that the information gathered was of limited value. The United States conducted several additional weapons tests with 233U for unknown purposes. The Soviet Union detonated its first hydrogen bomb the same year, the RDS-37, which contained a fissile core of 235U and 233U. In 1998, as part of its Pokhran-II tests, India detonated an experimental 233U device of low-yield (0.2 kt) called Shakti V. The B Reactor and others at the Hanford Site optimized for the production of weapons-grade material have been used to manufacture 233U. The United States Atomic Energy Commission used the weapons production reactors at Hanford to breed significant quantities of 233U from thorium for use in both nuclear weapons and for civilian research. Overall the United States is thought to have produced two tons of 233U, of various levels of purity, some with 232U impurity content as low as 6 ppm. The hazards are significant even at 5 parts per million. Implosion nuclear weapons require 232U levels below 50 ppm (above which the 233U is considered "low grade"; cf.
== Pharmacology == Teneligliptin has unique J-shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme. Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.
== Role in KLA == In 1993, Thaçi became a member of the inner circle of the KLA. The charisma of leaders such as Thaçi helped the KLA gain support from Kosovo Albanians. On 22 May 1993, together with Ilaz Kodra, Thaçi led an attack in Glogovac against Serbian police. The attack was a victory for the KLA; five officers were killed and two were injured. Thaçi (nom de guerre "Gjarpëri" − The Snake) was responsible for securing financial means and armaments, and training recruits in Albania to be dispatched to Kosovo. On 11 July 1997, Thaçi was tried in absentia and convicted by the district court in Pristina for terrorism associated with his activities in the KLA, and sentenced to 10 years in prison. Thaçi participated in the Battle of Rezalla, the KLA's first major battle, which occurred on 25 November. Many Yugoslav fighters were killed and their artillery and vehicles damaged after they were ambushed by KLA insurgents led by Adem Jashari. As a result, Yugoslav forces retreated to the village of Llausha where they shot two Albanian teachers who worked in the primary school of the village. In March 1999, Thaçi participated in the Rambouillet negotiations as the leader of the Kosovar Albanian team. Thaçi was perceived by western diplomats during the negotiations as the "voice of reason" within the KLA; his attendance demonstrated a willingness to accept autonomy for Kosovo within Serbia at a time when other rebel leaders rejected any solution short of full national independence.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.